Clinical Trial

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma. A small exploratory cohort of patients with GD2-positive tumors other than Neuroblastoma has also been included.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-12-08; most recent amendment 2025-02-03.
Status change: Recruiting → Active, Not Recruiting 2025-02-03
Status change: Not Yet Recruiting → Recruiting 2017-12-23
Trial Details
NCT Number NCT03373097
Lead Sponsor Bambino Gesù Hospital and Research Institute
Conditions Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors, Osteosarcoma, Ewing Sarcoma, Sarcoma
Enrollment 42 participants
Start Date 2018-01-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-05